Compare Abeona Therapeutics Inc (ABEO) vs Invesco DB Commodity Index Tracking Fund (DBC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Invesco DB Commodity Index Tracking Fund — how do they compare? Abeona Therapeutics Inc trades at $6.75 (market cap $373.32M), while Invesco DB Commodity Index Tracking Fund trades at $27.75. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, Invesco DB Commodity Index Tracking Fund nearer its low. Which is the better fit depends on your goals.
| ABEO | DBC | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $7.23 | $31.69 |
52-Week Low | $4.17 | $21.62 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
DBC trades at $27.00, up 1.62% with a bullish technical signal supported by strong momentum indicators. The commodity ETF shows resilience amid inflation concerns, recently hitting 52-week highs according to Zacks Investment Research (April 29, 2026). Current price action consolidates near key support/resistance levels with mixed moving average signals suggesting near-term consolidation potential.
Outlook remains positive as commodities gain traction for inflation hedging, though the ETF faces headwinds from commodity price volatility and geopolitical risks. The equal-weight portfolio strategy showing strong 2026 performance provides additional tailwinds for diversified commodity exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Invesco DB Commodity Index Tracking Fund
DBC is a diversified commodity ETF that tracks the DBIQ Optimum Yield Diversified Commodity Index. It invests in futures contracts for 14 heavily traded commodities, including crude oil, gold, and corn, while optimizing for yield and roll costs.
Read more on DBC →
